Immuno-oncology biotech developing targeted cancer immunotherapies
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Series A Israeli biotech Nectin Therapeutics raised a $25M Series A extension co-led by IBF and Peregrine Ventures to fund clinical evaluation of its PVR blocker NTX1088. | $25M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.